1. Home
  2. ETS vs APVO Comparison

ETS vs APVO Comparison

Compare ETS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ETS

Elite Express Holding Inc.

N/A

Current Price

$0.53

Market Cap

9.0M

Sector

Industrials

ML Signal

N/A

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$8.26

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETS
APVO
Founded
2020
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
8.3M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
ETS
APVO
Price
$0.53
$8.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
83.3K
407.4K
Earning Date
04-14-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,585,885.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.59
N/A
52 Week Low
$0.49
$7.66
52 Week High
$4.23
$1,688.40

Technical Indicators

Market Signals
Indicator
ETS
APVO
Relative Strength Index (RSI) 49.09 59.76
Support Level $0.52 $8.49
Resistance Level $0.58 $9.11
Average True Range (ATR) 0.03 0.83
MACD 0.00 -0.29
Stochastic Oscillator 38.07 18.09

Price Performance

Historical Comparison
ETS
APVO

About ETS Elite Express Holding Inc.

Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients' doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable, and innovative delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: